A Multicenter, Randomized, Double Blind, Pramipexole Controlled Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients with Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia

Trial Profile

A Multicenter, Randomized, Double Blind, Pramipexole Controlled Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients with Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia

Discontinued
Phase of Trial: Phase II

Latest Information Update: 19 Oct 2012

At a glance

  • Drugs Pardoprunox; Pramipexole
  • Indications Parkinson's disease
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 14 Apr 2012 Planned number of patients changed from 44 to 50 as reported by European Clinical Trials Database.
    • 14 Apr 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 01 Jul 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top